Yann Godfrin

This inventor holds 17 USPTO granted patents and 15 published patent applications, plus 12 CIPO patents and 13 EPO patents. Top assignees: Erytech Pharma, Becton Dickinson Infusion Therapy Systems Inc., Geneohm Sciences, Inc.. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yann Godfrin. Retrieved from https://idiyas.com/inventor/yann-godfrin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 15)

% Patents Active = 82.4

CIPO Patents = 12 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 21)

Average Co-Inventor Count = 1.9

ph-index = 7

Forward Citations = 166(Granted Patents)

Company Filing History:

Becton Dickinson Infusion Therapy Systems Inc.

patent

1 out of 14

Geneohm Sciences, Inc.

patents

Years Active: 2013-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11458170 - Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor (2022-10-04),

2. 11141468 - Method of treating a mammal, including human, against cancer using methionine and asparagine depletion (2021-10-12),

3. 10780151 - Composition and therapeutic anti-tumour vaccine (2020-09-22),

4. 10780126 - Pharmaceutical kit comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor (2020-09-22),

5. 10286008 - Method for stabilising suspensions of red blood cells encapsulating an active ingredient (2019-05-14),

6. 10273444 - Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes (2019-04-30),

7. 10046009 - Method of treatment using a pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and its cofactor (2018-08-14),

8. 9968663 - Erythrocytes containing arginine deiminase (2018-05-15),

9. 9950049 - Composition and therapeutic anti-tumour vaccine (2018-04-24),

10. 9580739 - Test for predicting neutralization of asparaginase activity (2017-02-28),

11. 9364504 - Compostition and therapeutic anti-tumour vaccine (2016-06-14),

12. 9125876 - Erythrocytes containing arginine deiminase (2015-09-08),

13. 8974802 - Medicament for the treatment of cancer of the pancreas (2015-03-10),

14. 8852880 - Test for predicting neutralization of asparaginase activity (2014-10-07),

15. 8822211 - Device and method for concentrating and detecting pathogenic microbes from blood products and/or their derivatives (2014-09-02),

Title: Exploring the Innovative Insights of French Inventor Yann Godfrin

Introduction: Yann Godfrin, a prolific inventor hailing from Lyons, France, has made a remarkable impact in the realm of pharmaceutical compositions and cancer treatments.

Latest Patents:

1. Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme: Yann Godfrin's groundbreaking invention focuses on a pharmaceutical composition containing a PLP-dependent enzyme encapsulated within erythrocytes. This invention opens new doors for drug development and therapeutic treatments.

2. Method of treating a mammal against cancer using methionine and asparagine depletion: Another notable patent of Yann Godfrin involves a novel method for combating liquid and solid cancers in mammals, including humans, through the strategic administration of methioninase before asparaginase. This innovative approach showcases his dedication to advancing cancer treatment methods.

Career Highlights: Yann Godfrin has accumulated an impressive portfolio of 17 patents, highlighting his expertise and dedication to innovation. His contributions in the fields of pharmaceuticals and cancer treatments have paved the way for novel therapeutic interventions and drug development.

Collaborations: Throughout his career, Yann Godfrin has collaborated with esteemed companies such as Erytech Pharma and Geneohm Sciences, Inc. His partnerships with industry leaders have fostered a dynamic environment for innovation and research. Some of his notable coworkers include Vanessa Bourgeaux and Fabien Gay, who have played pivotal roles in his groundbreaking projects.

Conclusion: Yann Godfrin's inventive spirit and dedication to advancing pharmaceutical compositions and cancer treatments have significantly impacted the healthcare industry. His collaborations with top-tier companies and talented coworkers underscore his commitment to driving innovation forward, making him a pioneering figure in the field of medical research.

Profile summary based on public USPTO records.